Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$2.71 -2.2%	$3.07	$1.05 ▼ $3.97	$274.72M	1.92	630,070 shs	668,910 shs
ALLO Allogene Therapeutics	$1.08 -12.2%	$1.28	$0.86 ▼ $3.78	$269.04M	0.35	3.85 million shs	19.09 million shs
ALT Altimmune	$3.61 -2.2%	$5.14	$2.90 ▼ $11.16	$299.29M	-0.01	3.61 million shs	1.80 million shs
IMMX Immix Biopharma	$2.65 -2.6%	$2.48	$1.26 ▼ $3.20	$75.83M	0.28	211,613 shs	181,085 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-2.34%	-17.50%	-3.90%	+87.54%	-18.62%
ALLO Allogene Therapeutics	-12.20%	-28.00%	-10.00%	-36.47%	-63.27%
ALT Altimmune	-2.17%	-11.52%	-26.33%	-37.44%	-43.24%
IMMX Immix Biopharma	-2.57%	-2.21%	+9.96%	+26.19%	+28.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.3772 of 5 stars	3.5	1.0	0.6	0.8	0.6
ALLO Allogene Therapeutics	3.1225 of 5 stars	4.5	2.0	1.5	2.5	0.6
ALT Altimmune	2.2481 of 5 stars	3.4	3.0	1.3	1.7	0.6
IMMX Immix Biopharma	2.6111 of 5 stars	3.5	3.0	0.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	185.98% Upside
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	681.89% Upside
ALT Altimmune	2.75	Moderate Buy	$18.20	404.16% Upside
IMMX Immix Biopharma	3.00	Buy	$7.00	164.15% Upside

Current Analyst Ratings Breakdown

Latest IMMX, ALT, ADCT, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ALT Altimmune	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
7/10/2025	ALT Altimmune	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $15.00
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	3.79	N/A	N/A	($2.10) per share	-1.29
ALLO Allogene Therapeutics	$20K	11,811.42	N/A	N/A	$2.01 per share	0.54
ALT Altimmune	$20K	14,640.36	N/A	N/A	$1.74 per share	2.07
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
ALT Altimmune	-$95.06M	-$1.26	N/A	N/A	N/A	-451,200.00%	-65.44%	-58.43%	8/6/2025 (Estimated)
IMMX Immix Biopharma	-$21.61M	-$0.70	N/A	N/A	N/A	N/A	-130.02%	-86.33%	8/11/2025 (Estimated)

Latest IMMX, ALT, ADCT, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ALT Altimmune	-$0.3006	N/A	N/A	N/A	$0.00 million	N/A
8/11/2025	Q1 2025	IMMX Immix Biopharma	-$0.21	N/A	N/A	N/A	N/A	N/A
8/6/2025	N/A	ALLO Allogene Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	N/A	N/A	N/A	$17.82 million	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.46	4.16
ALLO Allogene Therapeutics	N/A	9.71	9.71
ALT Altimmune	N/A	15.85	15.85
IMMX Immix Biopharma	N/A	1.80	1.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
ALLO Allogene Therapeutics	83.63%
ALT Altimmune	78.05%
IMMX Immix Biopharma	11.26%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
ALLO Allogene Therapeutics	13.20%
ALT Altimmune	4.10%
IMMX Immix Biopharma	55.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
IMMX Immix Biopharma	9	27.88 million	12.43 million	Optionable

IMMX, ALT, ADCT, and ALLO Headlines

Recent News About These Companies

Immix Biopharma (NASDAQ:IMMX) Trading 1.9% Higher - Still a Buy?

July 31 at 3:56 AM | marketbeat.com

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

July 11, 2025 | globenewswire.com

Immix Biopharma (NASDAQ:IMMX) Stock Price Up 1.5% - Here's Why

July 9, 2025 | marketbeat.com

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - Morningstar

July 8, 2025 | morningstar.comM

Immix Biopharma, Inc.: Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

July 8, 2025 | finanznachrichten.de $https://www.finanznachrichten.de/nachrichten-2025-07/65845168-immix-biopharma-inc-immix-biopharma-announces-accelerated-nexicart-2-clinical-trial-progress-in-relapsed-refractory-al-amyloidosis-399.htm$

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

July 7, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/07/07/3111088/0/en/immix-biopharma-announces-accelerated-nexicart-2-clinical-trial-progress-in-relapsed-refractory-al-amyloidosis.html$

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?

June 6, 2025 | zacks.com

Immix Biopharma Attends FDA CEO Forum in Washington DC

June 6, 2025 | globenewswire.com

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

June 6, 2025 | msn.com

Immix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025

June 5, 2025 | nasdaq.com

Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial

June 4, 2025 | msn.com

Immix Biopharma Enters At The Market Offering Agreement

June 3, 2025 | tipranks.com

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

June 3, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/03/3093133/0/en/immix-biopharma-announces-primary-endpoint-met-in-positive-nxc-201-interim-results-presented-at-asco-enabling-path-to-best-in-class-therapy-for-relapsed-refractory-al-amyloidosis.html$

Immix Biopharma Inc.

May 27, 2025 | wsj.com

Immix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL Amyloidosis

May 24, 2025 | nasdaq.com

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

May 23, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/05/23/3087484/0/en/immix-biopharma-further-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosis-trial-nexicart-2.html$

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

May 22, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/05/22/3087082/0/en/immix-biopharma-announces-positive-results-for-nxc-201-at-asco-oral-presentation-enabling-pathway-to-best-in-class-therapy-for-relapsed-refractory-al-amyloidosis.html$

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

May 21, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/05/21/3086145/0/en/immix-biopharma-to-host-kol-event-to-discuss-nxc-201-clinical-data-presented-at-asco-2025-in-relapsed-refractory-al-amyloidosis.html$

We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

May 19, 2025 | finance.yahoo.com

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

April 23, 2025 | globenewswire.com

Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright

February 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Rocket Lab: A Parabolic Run Meets a Healthy Pullback
By Ryan Hasson | July 23, 2025
View Rocket Lab: A Parabolic Run Meets a Healthy Pullback
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
Do They Know Something? Insiders & Congress Buy UnitedHealth
By Brian O'Connell | July 9, 2025
View Do They Know Something? Insiders & Congress Buy UnitedHealth
Insiders Spent Millions on These 3 Stocks Over the Past 2 Months
By Leo Miller | July 17, 2025
View Insiders Spent Millions on These 3 Stocks Over the Past 2 Months
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
By Gabriel Osorio-Mazilli | July 23, 2025
View Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

IMMX, ALT, ADCT, and ALLO Company Descriptions

ADC Therapeutics NYSE:ADCT

$2.71 -0.06 (-2.17%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$2.87 +0.16 (+6.05%)

As of 08/1/2025 07:44 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Allogene Therapeutics NASDAQ:ALLO

$1.08 -0.15 (-12.20%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.08 -0.01 (-0.46%)

As of 08/1/2025 07:44 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Altimmune NASDAQ:ALT

$3.61 -0.08 (-2.17%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.64 +0.04 (+0.97%)

As of 08/1/2025 07:58 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Immix Biopharma NASDAQ:IMMX

$2.65 -0.07 (-2.57%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.64 0.00 (-0.19%)

As of 08/1/2025 04:04 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time